Open AccessFirst COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
Author(s) -
Andra Fortner,
David Schumacher
Publication year - 2021
Publication title -
discoveries
Language(s) - English
Resource type - Journals
ISSN - 2359-7232
DOI - 10.15190/d.2021.1
Subject(s) - covid-19 , pandemic , authorization , medicine , quarantine , coronavirus , pneumonia , virology , intensive care medicine , disease , environmental health , medical emergency , infectious disease (medical specialty) , computer security , outbreak , pathology , computer science
On December 31, 2019, the Wuhan Municipal Health Commission reported an increase in the incidence of pneumonia from an unknown cause. Shortly after, SARS-CoV-19 was identified as the responsible coronavirus for the heavy progress of the disease, which can manifest itself distinctively in different individuals. Coronavirus Disease 2019 (COVID-19) triggered a pandemic because of its high contagiousness before COVID-19 associated symptoms actually appear. In response to the rapid and continuous spread of the virus around the globe governments have mobilized their forces to restrict contact and thus avoid further infection and invested significant resources in treatment and prevention strategies to tackle COVID-19. As a result, US FDA and EMA have granted emergency use authorization for two mRNA-based vaccines, namely the vaccines developed by BioNTech/Pfizer and Moderna, for use in the USA and Europe. Due to the existing critical situation, the stages of vaccine development and testing have probably never been gone through so fast as at present. Here, we are briefly commenting on these two vaccines with their benefits, advantages and limitations.